Newsletter Tool

Today's Rundown

With 200M unused doses, AstraZeneca's COVID vaccine partner Serum Institute halts production
HCA Healthcare lowers 2022 guidance, citing high labor costs, COVID cases, inflation
Intuitive Surgical pulls off 15% revenue growth despite ongoing COVID, supply chain challenges
Vallon looks for escape route a month after sole clinical asset fails in clinic
BioMarin joins pharma's filmmaking push with hemophilia documentary project
After manufacturing hiccup, Revance set for September FDA decision on Botox rival
Astellas takes $170M hit as DMD gene therapy plan unravels in wake of preclinical data
South Korean imaging AI developer Lunit outlines plans to go public
DOJ charges 21 defendants with COVID-related healthcare fraud schemes totaling $149M
The Clever-1? Faron hails melanoma data despite lack of responses
Quanterix's blood test for multiple sclerosis relapse risk nabs FDA breakthrough nod
After Brexafemme approval, Scynexis touts data that could broaden the antifungal's reach
NexHealth hits unicorn status with $125M series C for patient experience platform

Featured Story

With 200M unused doses, AstraZeneca's COVID vaccine partner Serum Institute halts production

By Angus Liu

About 200 million doses of COVID-19 vaccine are gathering dust in warehouses of the world’s largest vaccine manufacturer as global demand ebbs.

HCA Healthcare lowers 2022 guidance, citing high labor costs, COVID cases, inflation

By Dave Muoio

The major hospital chain's realignment comes alongside reduced Q1 2022 earnings despite higher revenues and encouraging volume trends.

Intuitive Surgical pulls off 15% revenue growth despite ongoing COVID, supply chain challenges

By Andrea Park

The year-over-year growth stemmed from a 19% surge in the number of procedures performed around the world using Intuitive’s da Vinci robotic surgery system.

Vallon looks for escape route a month after sole clinical asset fails in clinic

By Max Bayer

A month after Vallon Pharmaceuticals' one and only clinical-stage asset failed its first phase 1 test, the company is looking for an escape route to save the business. Vallon has tapped a law firm and investment bank to help with a strategic review, with the goal of finding any and all opportunities to stay afloat.

BioMarin joins pharma's filmmaking push with hemophilia documentary project

By Ben Adams

First came "Hemophilia: The Musical." Now, BioMarin is looking to inspire the next generation of filmmakers while creating a new documentary about the bleeding disorder.

After manufacturing hiccup, Revance set for September FDA decision on Botox rival

By Zoey Becker

After delays and setbacks for Revance, the FDA accepted its latest submission for a potential rival to AbbVie's Botox.

Astellas takes $170M hit as DMD gene therapy plan unravels in wake of preclinical data

By Nick Paul Taylor

Astellas’ gene therapy strategy is sinking deeper into the mire. Having reviewed the data on its Duchenne muscular dystrophy (DMD) therapies, the Japanese drugmaker has decided to scrap the candidates, triggering a $170 million impairment loss.

South Korean imaging AI developer Lunit outlines plans to go public

By Conor Hale

Lunit’s lead products include AI for analyzing mammograms and tissue slides for cancer as well as scanning X-ray images for common chest conditions.

DOJ charges 21 defendants with COVID-related healthcare fraud schemes totaling $149M

By Dave Muoio

Wednesday's charges ranged from improper use of personal identification collected during a COVID-19 test to schemes targeting the Provider Relief Fund.

The Clever-1? Faron hails melanoma data despite lack of responses

By Nick Paul Taylor

Faron Pharmaceuticals has posted data on its tumor-associated macrophage candidate bexmarilimab, linking the antibody to one unconfirmed partial response in a cohort of 11 checkpoint inhibitor refractory melanoma patients.

Quanterix's blood test for multiple sclerosis relapse risk nabs FDA breakthrough nod

By Andrea Park

In the most common form of multiple sclerosis, periods of stable remission are interrupted by relapses of new or worsening symptoms that last at least 48 hours. Quanterix’s test is designed to look for signs that a patient will relapse within the next four years.

After Brexafemme approval, Scynexis touts data that could broaden the antifungal's reach

By Kevin Dunleavy

Scynexis hit the market eight months ago with Brexafemme, a game-changing treatment for vaginal yeast infection. Now the New Jersey drugmaker is delivering data for the oral drug that may help broaden its antifungal reach. Interim results from the phase 3 Furi and Cares studies show the ability of ibrexafungerp to combat refractory fungal infections in hospitalized patients.

NexHealth hits unicorn status with $125M series C for patient experience platform

By Rebecca Torrence

NexHealth has joined the ranks of health tech unicorns with its $125 million series C round, boosting its valuation to $1 billion to support the expansion of its patient experience platform.

PM Tracker